Rigetti (RGTI) Q1 2026 Earnings Call Transcript

Rigetti reported Q1 revenue of $4.4 million, up from $1.5 million year over year, driven by on-premises QPU deliveries and government/research projects, while maintaining a debt-free balance sheet with $569.0 million in cash, cash equivalents, and investments. The company also launched its generally available 108-qubit CPS-108Q system on Amazon Braket, Azure Quantum, KubeRay, and Rigetti QCS, and guided to continued high CapEx plus recognition of an $8.4 million India order and remaining Nuvera revenue in 2026. Despite a $26.0 million operating loss and $14.7 million non-GAAP net loss, the technical progress and commercialization milestones support a constructive near-term outlook.

Analysis

The market is likely to misread this as a pure “technical milestone” story, but the more important second-order effect is commercial de-risking. A 100+ qubit system available on multiple cloud rails means Rigetti is no longer selling only promise; it is now competing for workflow lock-in, benchmark visibility, and developer mindshare against much larger compute platforms. That shifts the debate from whether superconducting chips can scale to whether Rigetti can become the default experimental substrate before larger incumbents bundle quantum access into broader cloud relationships.

The near-term earnings profile still looks lumpy, but that’s increasingly a feature, not a bug: each large on-prem order and acceptance test creates a step-function in reported revenue while the underlying installed base quietly expands recurring usage. The key hidden leverage is services pull-through: once a lab or government buyer installs hardware, the follow-on spend on controls, refrigeration, maintenance, and future chip refreshes should outgrow the initial system ticket. If execution holds, the mix should gradually shift from one-off system sales toward a higher-quality installed-base annuity, which the current valuation likely does not fully discount.

The biggest risk is that the road map is now being priced as if each incremental fidelity gain is linear and repeatable. It usually isn’t: coherence improvements, packaging, and control-stack integration tend to be nonlinear and can stall for quarters, which would expose the stock to sharp multiple compression if 99.5% slips past year-end or if the higher-fidelity 108Q slips. The UK spend is also a near-term dilution trap: it improves strategic positioning, but it will likely pressure cash burn and could force the market to reframe the story from “breakthrough platform” to “well-capitalized R&D program.”

Contrarian take: the consensus underestimates how much Amazon Braket matters. Being the first >100-qubit gate-based system on that platform is not just a vanity label; it creates a distribution wedge into AWS-native research budgets and could accelerate usage relative to direct sales. The flip side is that AMZN benefits more cleanly than RGTI if quantum becomes a meaningful cloud workload category, because AWS captures the orchestration layer and customer relationship even if Rigetti owns the hardware stack.

Key Decisions for Investors

• Long RGTIW on 3-6 month horizon into any post-earnings consolidation; thesis is that cloud distribution + on-prem order backlog should support multiple revenue prints, with upside if fidelity progress holds. Risk/reward: attractive if you size for 20-30% upside versus 15% downside on a stalled-road-map reset.
• Buy AMZN vs RGTI as a structural pair trade over 6-12 months; if quantum usage expands, AWS monetizes the platform layer regardless of hardware winner. This captures the pick-and-shovel beneficiary while limiting exposure to execution risk at the chip level.
• Short-dated RGTIW puts or put spreads if the stock rallies sharply on the headline over the next 2-4 weeks; the stock is vulnerable to ‘sell the news’ once investors refocus on burn, timing risk, and diluted path to quantum advantage.
• Use NVDA as a cleaner way to express quantum-enablement optionality only on pullbacks; NVIDIA’s ecosystem exposure is broader and less binary than RGTI, with better downside protection if quantum timelines slip by 1-2 years.
• Avoid initiating a large short in RGTIW outright until there is evidence of either missed fidelity milestones or UK capex-driven burn reacceleration; the balance sheet reduces near-term squeeze risk and can keep the equity elevated on narrative alone.